Slide 1: Investors' and Analysts' Conference Call FY 2021
INVESTORS’ AND ANALYSTS’ CONFERENCE CALL FY 2021 Grünwald, 12 April 2022
Slide 2: Agenda FY 2021
AGENDA FY 2021 1. Highlights 2021 2. Financial figures 2021 3. Outlook 2022 4. Q&A 2
Slide 3: Highlights
Highlights 3
Slide 4: Highlights 2021
Highlights 2021 Dermapharm continues its successful growth course Vaccine production Ongoing vaccine production in Brehna and Reinbek – investment in production equipment for “fill & finish” in Q4 2021 in Brehna – start of “fill & finish” process in Q1 2022 HIGHLIGHTS Strengthening of segment Herbal
Slide 5: Highlights 2021 – segment branded pharmaceuticals
Highlights 2021 – segment branded pharmaceuticals Allergopharma with significant revenue and market share growth Significant revenue growth1 Market share growth2 Restructuring measures at Allergopharma Allergovit SCIT Pollen show first effects: significant worldwide +17.6% market revenue growth Yo
Slide 6: Highlights 2021 – segment branded pharmaceuticals
Highlights 2021 – segment branded pharmaceuticals Further strengthening of our market presence Unique preparations Market leadership Providing real added value High demand in pharmacies … for women‘s and male disorders No.1 based on revenues1 Growth driver Chronic Prostate Pain Recurring Urinary tra
Slide 7: Financial figures 2021
2 Financial figures 2021 ———— Fe =. ae Ny ee eee om ee
Slide 8: Highlights FY 2021
Highlights FYR 2021 Delivering on our guidance 2021 – targets achieved despite challenging developments Guidance 2021 FYR 2021 + 15% to + 20% + 18.8% Revenues vs. previous year (€793.8m) (€942.9m) + 70% to + 75% + 74.9% EBITDA1 (adjusted) vs. previous year (€200.7m) (€351.1m) 1 EBITDA FY 2020 ad
Slide 9: Dermapharm Group
Dermapharm Group Continuous growth, while COVID-19 pandemic is going on Total Revenue EBITDA1 Significant revenue growth of 18.8% to €m €m, adjusted €942.9m, due to +18.8% 37.2% vaccine production in cooperation with YoY EBITDA BioNTech SE Margin revenue contribution of acquisition 942.9 25.3% A
Slide 10: Branded pharmaceuticals and other healthcare products
Branded pharmaceuticals and other healthcare products Strong growth due to the successful cooperation with BioNTech SE Revenue EBITDA1 Significant revenue growth of 35.9% to €m €m, adjusted €640.4m, due to +35.9% 52.5% vaccine production in cooperation with YoY EBITDA BioNTech SE 640.4 Margin 39.1
Slide 11: Herbal extracts
Herbal extracts Lower demand due to COVID-19 pandemic Revenue EBITDA1 Revenue growth of 0.1% to €72.0m, due to €m €m, adjusted recovering demand offset by FX rate +0.1% 26.9% effects (EUR/USD) YoY EBITDA 72.0 Margin strong growth in American and Asian 21.1% markets, while Europe still behind 71.
Slide 12: Parallel import business
Parallel import business Declining market and regulatory changes impact results Revenue EBITDA Revenue decreased by 8.0% to €230.6m, €m €m, adjusted due to -8.0% declining PI market YoY 2.8% 230.6 continuous growth in the OTC, narcotics EBITDA 0.9% and medical cannabis could not offset the Margi
Slide 13: Earnings before tax (Group EBT)
Earnings before tax (Group EBT) Result increases due to vaccine production and improved financial covenant Earnings before tax (EBT)1 EBT increased by 133.8% to €293.0m €m (unadjusted) resulting in a margin of 31.1% 31.1% EBT Margin 15.8% Mainly influenced by disproportional increase of deprecia
Slide 14: Strong cash flows and cash conversion
Strong cash flows and cash conversion Dedication to future growth Cash flow and cash conversion1 CF from operating activities mainly €m and in % of Group EBITDA influenced by increased EBT in FY 2021 71.3% Cash conversion CF from investing activities reflecting 65.3% Acquisition of Cernelle an
Slide 15: Balance Sheet of Dermapharm Group
Balance Sheet of Dermapharm Group Balance sheet as of 31 December 2021 Total assets increased to €1,407m €m 2 (31 December 2020: €1,224m) 1,407 1,407 Non-current assets increased to €888m (31 December 2020: €824m) Equity Current assets increased to €519m (31 December 2020: €400m), mainly due t
Slide 16: Outlook 2022
3 Outlook 2022
Slide 17: Outlook 2022 – Growth strategy
Outlook 2022 Growth strategy on track Growth rates are based on organic growth supported by new launches of in-house developments. Guidance for the FY 2022 also includes Growth $ growth impulses from M&A deals and the existing cooperation with BioNTech of strategy COVID-19 vaccine production.
Slide 18: Q&A
4 Q&A 18
Slide 19: Financial calendar
Financial calendar 2022 Annual Report 2021 CSR Report 2021 Analysts‘ and Investors‘ Call FY 2021 Annual General Half-year Financial Report Meeting 2022 as at 30 June 2022 2022 12 April 1 June 7 September 22 / 29 March 18 May 23 August 16 November 2023 Quarterly Statement Quarterly Statement as at 31
Slide 20: Disclaimer
Disclaimer This publication includes statements, estimates, opinions and projections with respect to the anticipated future performance of Dermapharm Holding SE (together with its consolidated subsidiaries, “Dermapharm”) and such statements, estimates, opinions and projections (“Forward-Looking Stat
Slide 21: For information, please contact
For information, please contact Britta Hamberger Investor Relations & Corporate Communications Dermapharm Holding SE E-Mail: ir@dermapharm.com Phone: +49 (0) 89 641 86 233 Dermapharm FY 2021 21